⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2123312 | 0.83 | ALDH1A1 (0.44) | — | |
| SCHEMBL1298475 | 0.80 | — | — | |
| SCHEMBL27849243 | 0.78 | TDP1 (0.43) | — | |
| SCHEMBL16885822 | 0.78 | ALDH1A1 (0.39) | — | |
| SCHEMBL16629261 | 0.73 | — | — | |
| SCHEMBL6156439 | 0.73 | — | — | |
| SCHEMBL13063487 | 0.73 | — | — | |
| SCHEMBL13456844 | 0.73 | — | — | |
| SCHEMBL12036099 | 0.73 | — | — | |
| SCHEMBL5268365 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| WO-2017049401-A1 | NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS | PHARMASCIENCE INC. (CA) | 2017-03-30 | — | — | WO | disclosed |
| WO-2016187723-A1 | INHIBITORS OF THE TEC KINASE ENZYME FAMILY | PHARMASCIENCE INC. (CA) | 2016-12-01 | — | — | WO | disclosed |
| US-20160130260-A1 | TERT-BUTYL SULPHOXIDE METHOD FOR PRODUCING FESTINAVIR | BRISTOL MYERS SQUIBB CO (US) | 2016-05-12 | — | — | US | disclosed |
| WO-2015169233-A1 | INHIBITOR OF BRUTON'S TYROSINE KINASE | 北京赛林泰医药技术有限公司 | 2015-11-12 | — | — | WO | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2011009934-A1 | TRIS(1,2,3-TRIAZOL-4-YL)METHANE ORGANOMETALLIC COMPOUNDS AS CATALYSTS AND PROCESSES USING THEM. | INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ICIQ) (ES) | 2011-01-27 | — | — | WO | disclosed |
| US-20090069569-A1 | CYCLOADDITION OF AZIDES AND ALKYNES | INSTITUT CATALA D'INVESTIGACIO QUIMICA (ES) | 2009-03-12 | — | — | US | disclosed |
| US-20070117847-A1 | N-(3-(4-Substituted-1-piperiding1)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | CHAMBERS MARK S | 2007-05-24 | — | — | US | disclosed |
| US-7125887-B2 | Pyrrolidine modulators of CCR5 chemokine receptor activity | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040087552-A1 | Pyrrolidine modulators of ccr5 chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2004-05-06 | — | — | US | disclosed |
| US-20040002504-A1 | N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2004-01-01 | — | — | US | disclosed |
| EP-1326619-A2 | PYRROLIDINE MODULATORS OF CCR5 CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| WO-2003030898-A1 | MODULATORS OF CCR5 CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-6511994-B2 | For prophylaxis and therapy of infection by HIV and the treatment of AIDS | MERCK & CO., INC. | 2003-01-28 | — | — | US | disclosed |
| US-20020193407-A1 | Modulators of CCR5 chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-12-19 | — | — | US | disclosed |
| WO-2002034716-A2 | PYRROLIDINE MODULATORS OF CCR5 CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2002-05-02 | — | — | WO | disclosed |